✦ LIBER ✦

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

✍ Scribed by Francesco Caponigro; Pax Willemse; Roberto Sorio; Anne Floquet; Simon van Belle; Jan Demol; Rosa Tambaro; Alessandro Comandini; Angela Capriati; Sabine Adank; Jantien Wanders

Book ID: 111579941
Publisher: Springer US
Year: 2005
Tongue: English
Weight: 81 KB
Volume: 23
Category: Article
ISSN: 0167-6997
DOI: 10.1023/b:drug.0000047110.36382.45

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of MEN-10755 in patient

A phase II study of MEN-10755 in patients with advanced or metastatic ovarian cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Second-Line Treatment with Intravenous G

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

✍ Bruzzone, M.; Centurioni, M.G.; Giglione, P.; Gualco, M.; Merlo, D.F.; Miglietta 📂 Article 📅 2011 🏛 S. Karger AG 🌐 English ⚖ 469 KB

Phase II study of sunitinib as maintenan

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer

✍ Gervais, Radj; Hainsworth, John D.; Blais, Normand; Besse, Benjamin; Laskin, Jan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 264 KB

768 - Phase II study of a multi-targeted

768 - Phase II study of a multi-targeted antifolate (LY231514) (MTA) as first line therapy in patients with locally advanced or metastatic colorectal cancer (MCC)

✍ M.C. Cripps; M. Bumell; J. Jolivet; W. Lofters; B. Fisher; L. Panasci; J. Igiesi 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 263 KB

Phase I/II study of oral etoposide plus

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer

✍ Baur, M; Schernhammer, E; Gneist, M; Sevelda, P; Speiser, P; Hudec, M; Dittrich, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 109 KB

Phase II Study of Intravenous DX-8951f i

Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan

✍ C. F. VERSCHRAEGEN; C. LEVENBACK; M. VINCENT; J. WOLF; M. BEVERS; E. LOYER; A. P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB